Diaceutics (DXRX) Price & Analysis

Compare

10 Followers

DXRX Stock Chart & Stats

Day’s Range― - ―

52-Week Range106.00p - 159.00p

Previous CloseN/A

Volume29.93K

Average Volume (3M)139.03K

Market Cap

$128.53M

Enterprise Value90.09M

Total Cash (Recent Filing)$12.74M

Total Debt (Recent Filing)$1.06M

Price to Earnings (P/E)―

Beta0.61

Next Earnings

Mar 24, 2026

EPS Estimate

0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding84,880,394

10 Day Avg. Volume212,034

30 Day Avg. Volume139,034

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.70

Enterprise Value/Revenue2.80

Enterprise Value/Gross Profit3.44

Enterprise Value/Ebitda29.31

Forecast

1Y Price Target

$196.14

Price Target Upside22.58% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Contract NegotiationDiaceutics has successfully renegotiated its first PMx contract with the new commercial licensee, which is worth £4.5m in recurring service revenues.

Revenue GrowthAnother year of strong organic revenue growth in FY24 (+36% to £32.2m) and continued momentum into the first four months of 2025 (+35% to £8.4m), puts the business well on track to deliver on current revenue (+25%) and EBITDA expectations for FY25.

Strategic PartnershipsDiaceutics now works with 18 of the top 20 global pharma companies across 56 therapeutic brands, and during FY24 Diaceutics worked with 85 therapies across 52 customers.

Bears Say

Share Price VolatilityAnalyst sees the recent share pullback as a buying opportunity due to the business delivering very strong organic growth and trading on just 2.3x current FY25E EV/sales, despite its superior top-line growth.

Diaceutics News

Diaceutics Plc Reports Strong H1 2025 Performance

Diaceutics Plc ( ($DIUXF) ) has released its Q2 earnings. Here is a breakdown of the information Diaceutics...

3d ago

Diaceutics PLC Reports Strong H1 2025 Results, On Track for Profitability

Diaceutics ( ($GB:DXRX) ) has shared an announcement. Diaceutics PLC reported strong financial results for the first half...

3d ago

Diaceutics to Announce Half-Year Results and Host Investor Webinar

Diaceutics ( ($GB:DXRX) ) has provided an update. Diaceutics PLC announced it will release its unaudited half-year results...

16d ago

Diaceutics PLC Expands Share Incentive Plan with New Share Issuance

Diaceutics ( ($GB:DXRX) ) just unveiled an announcement. Diaceutics PLC has announced that Global Shares Trustees (UK) Limited...

25d ago

Diaceutics to Present at Canaccord Genuity Growth Conference

Diaceutics ( ($GB:DXRX) ) has issued an update. Diaceutics PLC announced its participation in the Canaccord Genuity 45th...

2M ago

Diaceutics Enhances Employee Incentives with Share Purchase Plan

The latest update is out from Diaceutics ( ($GB:DXRX) ). Diaceutics PLC has announced the purchase of ordinary...

2M ago

Diaceutics Appoints Lauren DeWitt as General Counsel

Diaceutics ( ($GB:DXRX) ) just unveiled an update. Diaceutics PLC has appointed Lauren DeWitt as Executive Vice President,...

2M ago

Diaceutics PLC Issues Share Options to Key Personnel

Diaceutics ( ($GB:DXRX) ) just unveiled an update. Diaceutics PLC has announced the issuance of 1,886,357 share options...

2M ago

Diaceutics Reports Strong H1 2025 Performance with 22% Revenue Growth

Diaceutics ( ($GB:DXRX) ) has provided an update. Diaceutics PLC reported a strong performance in the first half...

2M ago

Diaceutics Expands PMx Commercialization Partnership After Early Success

Diaceutics ( ($GB:DXRX) ) has shared an announcement. Diaceutics PLC has announced the expansion of its PMx commercialization...

2M ago

Diaceutics price target raised to 195 GBp from 165 GBp at RBC Capital

RBC Capital analyst Natalia Webster raised the firm’s price target on Diaceutics (DIUXF) to 195 GBp from 165...

8M ago

Diaceutics price target raised to 165 GBp from 145 GBp at RBC Capital

RBC Capital analyst Natalia Webster raised the firm’s price target on Diaceutics to 165 GBp from 145 GBp...

1y ago

DXRX FAQ

What was Diaceutics’s price range in the past 12 months?

Diaceutics lowest share price was 106.00p and its highest was 159.00p in the past 12 months.

What is Diaceutics’s market cap?

Diaceutics’s market cap is $128.53M.

When is Diaceutics’s upcoming earnings report date?

Diaceutics’s upcoming earnings report date is Mar 24, 2026 which is in 179 days.

How were Diaceutics’s earnings last quarter?

Diaceutics released its earnings results on Sep 23, 2025. The company reported -0.028p earnings per share for the quarter, the consensus estimate of -0.028p by 0p.

Is Diaceutics overvalued?

According to Wall Street analysts Diaceutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Diaceutics pay dividends?

Diaceutics does not currently pay dividends.

What is Diaceutics’s EPS estimate?

Diaceutics’s EPS estimate is 0.04.

How many shares outstanding does Diaceutics have?

Diaceutics has 84,880,394 shares outstanding.

What happened to Diaceutics’s price movement after its last earnings report?

Diaceutics reported an EPS of -0.028p in its last earnings report, expectations of -0.028p. Following the earnings report the stock price went up 4.605%.

Which hedge fund is a major shareholder of Diaceutics?

Currently, no hedge funds are holding shares in GB:DXRX

Company Description

Diaceutics

Diaceutics (DXRX) is a precision medicine company focused on improving patient outcomes through the integration of diagnostics into the development and commercialization of personalized medicine. Operating primarily in the healthcare and biotechnology sectors, Diaceutics provides services and solutions that enable pharmaceutical companies to effectively integrate diagnostic testing into their drug development processes. The company offers data analytics, laboratory testing, and consultancy services to optimize the use and development of companion diagnostics, which are crucial for delivering targeted therapies to patients.

Diaceutics (DXRX) Earnings & Revenues

Historic Earnings Reports

DXRX Company Deck

DXRX Earnings Call

Q4 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a mix of positive developments, particularly with revenue growth, high gross margins, and the strategic launch of the PMx solution, alongside record order book figures. However, challenges such as the increased EBITDA loss and decreased TCV were noted. The overall sentiment leans towards optimism, driven by strategic advancements and strong financial positioning.View all GB:DXRX earnings summaries

DXRX Stock 12 Month Forecast

Average Price Target

196.14p

▲(22.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"98":"98p","225":"225p","129.75":"129.8p","161.5":"161.5p","193.25":"193.3p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":224.05843838327175,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">224.06p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":196.13575645,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">196.14p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":179.2467507066174,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">179.25p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[98,129.75,161.5,193.25,225],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,140,146.46603372179013,152.93206744358028,159.3981011653704,165.86413488716053,172.33016860895066,178.7962023307408,185.26223605253094,191.72826977432106,198.19430349611122,204.66033721790134,211.12637093969147,217.59240466148162,{"y":224.05843838327175,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,140,144.31813511153845,148.63627022307693,152.9544053346154,157.27254044615384,161.5906755576923,165.90881066923077,170.22694578076923,174.54508089230768,178.86321600384616,183.18135111538462,187.49948622692307,191.81762133846155,{"y":196.13575645,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,140,143.01898082358596,146.0379616471719,149.05694247075786,152.07592329434382,155.09490411792976,158.11388494151572,161.13286576510168,164.15184658868765,167.17082741227358,170.18980823585954,173.2087890594455,176.22776988303144,{"y":179.2467507066174,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":99.5,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.5,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.5,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >